AstraZeneca Investor Day Presentation Deck
Best % Change in Sum of Diameters From Baseline
Efficacy: confirmed ORR and best overall response
100
80
60
40-
20
0
-20-
-40
-60
-80
-100
100
80
60
40
20
0
-20
-40-
-60
-80
-100
T-DXd (n = 245)¹
T-DM1 (n = 228)¹
CI, confidence interval; CR, complete response; DCR, disease control rate; PD, progressive disease; PR, partial response; SD, stable disease.
1. Only subjects with measurable disease at baseline and at least one postbaseline target lesion assessment are included. 2. Based on BICR.
11 Red line at 20% indicates progressive disease; black line at -30% indicates partial response.
Confirmed ORR
n (%)²
[95% CI]
CR
PR
SD
PD
Not evaluable
CR + PR + SD
(DCR)
T-DXd
(n = 261)
208 (79.7)
[74.3-84.4]
T-DM1
(n = 263)
42 (16.1)
166 (63.6)
44 (16.9)
3 (1.1)
6 (2.3)
252 (96.6)
90 (34.2)
[28.5-40.3]
P<.0001
23 (8.7)
67 (25.5)
112 (42.6)
46 (17.5)
15 (5.7)
202 (76.8)
3View entire presentation